Table 4.
Survival of patients treated with venetoclax and decitabine or azacytidine
| Survival | ||||
|---|---|---|---|---|
| All patients (N = 57) |
Decitabine-venetoclax (N = 35) |
Azacitidine-venetoclax (N = 22) |
Significance | |
| Median overall survival – m. | 8.2 m. | 5.7 m. | 8.3 m. | p = 0.425 |
| Progression-free survival – m. | 4.6 m. | 4.0 m. | 5.6 m. | p = 0.334 |
| Overall survival by ELN 2022 cytogenetic risk category – no. (%) | ||||
| FavorableA | 5.8 m. | 5.8 m. | — | — |
| Intermediate | 8.2 m. | 8.6 m. | 7.4 m. | p = 0.702 |
| Adverse | 8.3 m. | 4.5 m. | 10.5 m. | p = 0.086 |
A:
The overall survival for the favorable risk category is undefined in the azacitidine-venetoclax cohort (N = 1)